Our main approaches to immunotherapy is therapeutic DNA vaccines
DNA therapeutic vaccine technology, a globally competitive platform technology, is one of Genexine’s core proprietary technologies. Therapeutic vaccine is prepared by introducing antigen gene and dendritic cell targeting gene into high-efficiency expression vector. When administered, it induces antigen-specific immune response and therefore works as ‘therapeutic vaccine’ against infectious diseases and cancer.
Genexine has a long experience in developing therapeutic vaccines since 1999 and continues to improve therapeutic vaccines by adopting DNA delivery technology (electroporation) to efficiently maximize target gene expression in human body. Our current DNA vaccine pipeline includes vaccines targeting human papilloma virus (HPV) type 16 and 18 associated cervical intraepithelial neoplasia (CIN) which eventually causes cervical cancer.
With Genexine’s experience and expertise, we will provide first-in-class DNA therapeutic vaccine and wish to resolve the unmet medical needs of patients who previously experienced unsatisfactory results with conventional treatments.